Group Insurance Commission hears stewardship findings, declines major plan‑design cuts for drug and provider cost pressures

The Group Insurance Commission on Jan. 16 reviewed mid‑year stewardship reports from its carriers showing rising high‑cost claimants and prescription cost trends and discussed plan‑design changes the staff will bring forward for fiscal 2026. Commissioners approved the minutes from the December meeting and received a verbal update that the fund—s year‑to‑date deficit remains over $100 million.

Why it matters: The commission oversees health benefits for state employees, retirees and participating municipalities and is one of the state's largest purchasers of health care. Commission staff told members that the drivers of this year—s cost increases include high‑cost specialty drugs, growing use of GLP‑1 class medications, and rising hospital‑based prices, and that those pressures require purchasing‑ and market‑level fixes rather than sweeping plan‑design cuts that shift costs to members.

Executive director Matt (executive director) opened the meeting and led the executive‑director—s report outlining two recently enacted laws that affect the GIC: the PACT Act (prescription drug policy changes and expanded authority for the Health Policy Commission) and a separate law expanding market‑review authority for health care transactions. Matt noted staff will present plan‑design recommendations in February and said, “plan design is not primarily the right place to look for solutions to these much bigger and deeper problems,” a conclusion staff reached after evaluating options.

Cameron McBean, the GIC—s director of vendor management, summarized the stewardship meetings with the commission—s carriers and pharmacy benefit manager. He reported that Health New England experienced an unusually high allowed per‑member per‑month trend tied to an uptick in high‑cost claimants and greater inpatient and outpatient acuity; Point32 and Mass General Brigham also showed notable trends; and Caremark reported a high prescription trend for the non‑Medicare population. McBean said some variation reflected membership shifts (Mass General Brigham—s first year of broad statewide offering) and changes in drug utilization.

McBean and staff characterized the high‑cost claimant group (commonly defined by the industry as members with annual allowed costs above $100,000) as a recurring but volatile driver of short‑term trend. "These things tend to level out as we watch them over time," McBean said, while adding that for smaller carriers a single high‑cost case can materially affect near‑term performance.

On medications and plan design, staff proposed several incremental changes for FY26: add the Hinge Health digital musculoskeletal program through CVS, harmonize and expand fertility benefits (remove a prior requirement to demonstrate infertility before covering intrauterine insemination and IVF and expand cryopreservation coverage), and remove session limits on nutritional counseling required by the commission—s recent parity audit. Staff described the near‑term financial impact of those items as minimal; Willis Towers Watson—s estimates put the fertility enhancement at about a half‑percentage point on one large plan in a high‑case projection.

The recently enacted PACT Act will require the commission to change some formulary cost sharing for drugs used to treat certain chronic conditions, staff said. Andrew (staff member) told commissioners that, as written, the statute requires the commission to identify the "two most prevalent heart conditions" for the GIC membership to determine which drugs and copayment rules apply. Staff are analyzing internal claims and CVS prescription data and consulting Willis Towers Watson to select conditions consistent with the statute and clinical best practice. "The way the statute is written, it's actually the commission who is going to determine what those heart conditions are for its membership," Andrew said.

Commissioners pressed staff on GLP‑1 class medications (weight‑loss and metabolic drugs). Staff reviewed three broad responses they considered: exclude the drugs; increase member cost share; or pursue purchasing and clinical‑management alternatives. Staff reported that 1) several state employee plans nationwide cover GLP‑1s with prior authorization aligned to FDA approvals; 2) excluding the drugs would be an active policy choice with significant member impact; and 3) shifting costs to members by higher copays or deductibles risks equity problems and would not address marketplace pricing. Cameron McBean said the commission is pursuing manufacturer negotiations, enhanced prior‑authorization and adherence‑monitoring programs, and possible digital‑therapeutic or vendor models to manage access and cost. "We are not recommending excluding them from our coverage," McBean said.

On provider prices, staff reiterated that hospital‑owned outpatient services and a small number of high‑priced systems are the largest drivers of trend. They said previous site‑of‑service copay differentials produced limited results and member confusion. Staff proposed preparing system‑level strategies for FY27 that could include targeted narrow networks, center‑of‑excellence arrangements and procurement changes to favor carriers achieving better provider price outcomes. Matt said those strategies are multi‑year market interventions, not FY26 fixes.

Other business and next steps: staff noted a new municipal participant, the Town of Holliston, will join the GIC on July 1 (about 600 members). Staff reiterated the schedule: information sessions for members ahead of April 2–May 1 annual enrollment; a February 6 meeting to present plan‑design language; and a Feb. 27 meeting to vote on final rates. Jim (CFO) provided a brief verbal finance update: the deficit reported last month remains at more than $100 million and staff will provide full financial statements at the next meeting.

Votes at a glance: Commissioners approved the minutes from the December meeting (motion to approve minutes; mover: Bobby; second: Vice Chair Eileen Kaplan). Roll call recorded a majority of commissioners voting in the affirmative with two abstentions; staff announced the motion passed "unanimously of those voting." The commission took no other formal actions at the meeting.

The commission directed staff to continue the FY26 plan‑design work and to return in February with proposed plan language and rate recommendations after public information sessions and further analysis of PACT Act obligations and drug‑pricing strategies.

The meeting adjourned after commissioners were reminded to promote the public information sessions and the chair called for a motion to adjourn.